|Bid||3.2400 x 1000|
|Ask||3.5500 x 1800|
|Day's range||3.1900 - 3.3500|
|52-week range||2.7400 - 8.7400|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||2.22|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.00|
Lyell Immunopharma (LYEL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Lyell Immunopharma (LYEL) delivered earnings and revenue surprises of 17.65% and 99.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyell Immunopharma (LYEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.